Our data reported herein identify the immunostimulatory agent, Immunomax® as a TLR-4 agonist with anti-tumor activity in the stringent 4T1 murine breast cancer model, which recapitulates human micro-metastatic disease. The gene discussed is TLR4; the disease is metastatic neoplasm.